| Date | Title | | | 09/02/10 | Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate
Collaboration with Agensys, an Affiliate of Astellas| BOTHELL, Wash., Sep 02, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has
achieved a milestone under its antibody-drug conjugate (ADC)
collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas
Pharma Inc. The milestone was triggered by Agensys' initiation of a
phase I trial for AGS-16M8F, an ADC for the treatment of cancer
utilizing Seattle Genetics' technology.
"This trial initiation increases the t... |
|  | | 08/04/10 | Seattle Genetics to Present at the Canaccord Genuity 30th Annual Growth Conference| BOTHELL, Wash., Aug 04, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric L. Dobmeier, Chief Business Officer, will speak at the Canaccord Genuity 30th Annual Growth Conference on Tuesday, August 10, 2010, at 9:30 a.m. Eastern Time. A webcast of the presentation will be available from Seattle Genetics' website, http://www.seattlegenetics.com, under the "Investor and News" section.
About Seattle Genetics
Seattle Genetics is a clinical-stage biotechnology co... |
| | | 08/03/10 | Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech| Seattle Genetics to Receive $12 Million Upfront Payment, Over $900 Million in Potential Fees and Milestone Payments and Mid-Single Digit Royalties
BOTHELL, Wash., Aug 03, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY). Under the expanded agreement, Genentech will pay an upfront fee of $12 million f... |
| | | 07/27/10 | Seattle Genetics Reports Second Quarter 2010 Financial Results and Continued Pipeline Progress| Top-Line Data from Two Late-Stage Clinical Programs Anticipated During 2010; Strong Financial Position Driving Progress Across Broad Product Pipeline
Conference Call Today at 5:00 p.m. ET
BOTHELL, Wash., Jul 27, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter and six months ended June 30, 2010. The company also highlighted recent product development activities and upcoming milestones.
"We had a strong second quarter ... |
| | | 07/20/10 | Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer| BOTHELL, Wash., Jul 20, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
"There is significant need for new pancreatic cancer therapies, demonstrated by the fact t... |
| | | 07/19/10 | Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2010 Financial Results on July 27, 2010| BOTHELL, Wash., Jul 19, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2010 financial results on Tuesday, July 27, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Tuesday, July 27, 2010
2:00 p.m. Pacific Time (PT)... |
| | | 06/05/10 | Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma| Objective Responses and Tolerability Demonstrated in Retreatment Setting
CHICAGO, Jun 05, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achiev... |
| | | 06/02/10 | Seattle Genetics Announces Webcast Presentations at Upcoming Investor Conferences| BOTHELL, Wash., Jun 02, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present a company overview at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investor and News" section.
Jefferies 2010 Global Life Sciences Conference
Tuesday, June 8, 2010
1:00 p.m. Eastern Time
Ne... |
| | | 05/24/10 | Seattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL Trial|
Preliminary Data Anticipated in Second Half of 2010
BOTHELL, Wash. & CAMBRIDGE, Mass., May 24, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin i... |
| | | 05/24/10 | Seattle Genetics Names Vice President, Sales and Announces Management Promotion| BOTHELL, Wash., May 24, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Charles (Chip) R. Romp as Vice President, Sales. Mr. Romp brings more than 19 years of biotechnology and pharmaceutical sales and sales management experience to the company, most recently from Genentech, a wholly owned member of the Roche Group. In addition, the company announced the promotion of Jonathan Drachman, M.D., to Senior Vice President, Research and Translational Medic... |
| | | 05/21/10 | Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at the American Society of Clinical Oncology Annual Meeting| BOTHELL, Wash., May 21, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois. The presentation will highlight data from Hodgkin lymphoma and systemic anapl... |
| | | 04/28/10 | Seattle Genetics to Present at Upcoming Investor Conferences| SEATTLE, Apr 28, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that management will present at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investor and News" section.
Deutsche Bank Securities 35th Annual Health Care Conference
Eric L. Dobmeier, Chief Business Officer, will present a company overview on Wednesday, May 5, 2010, at 10:40 a.m.... |
| | | 04/27/10 | Seattle Genetics Reports First Quarter 2010 Financial Results|
Company in Strong Financial Position; Focused on Key Data in Remainder of Year and Continued Advancement of Its Broad Product Pipeline
Conference Call Today at 5:00 P.M. ET
BOTHELL, Wash., Apr 27, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.
"We ended the first quarter in a strong financial position, and ... |
| | | 04/21/10 | Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACR|
ASG-5ME Expected to Advance into Phase I Clinical Trials During 2010 for Prostate and Pancreatic Cancers
BOTHELL, Wash. & SANTA MONICA, Calif., Apr 21, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cance... |
| | | 04/21/10 | Seattle Genetics Highlights ADC and SEA Technologies at AACR| BOTHELL, Wash., Apr 21, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that research related to its antibody-drug conjugate (ADC) and sugar engineered antibody (SEA) technologies were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C. The presentations demonstrate the mechanism of action of SGN-75, an ADC, in preclinical models and describe a novel approach for efficient, large-scale screening o... |
| | | 04/20/10 | Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2010 Financial Results on April 27, 2010| BOTHELL, Wash., Apr 20, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its first quarter 2010 financial results on Tuesday, April 27, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Tuesday, April 27, 2010, 2:00 p.m. Pacific Time (PT) / ... |
| | | 04/20/10 | Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate Collaboration| BOTHELL, Wash., Apr 20, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targe... |
| | | 04/08/10 | Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma|
AETHERA Trial Designed to Support Full Approval in the United States and Europe
Data from Ongoing Pivotal Trial to Be Reported in Second Half of 2010 and Provide Basis for NDA and MAA Submissions in the First Half of 2011
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan, Apr 08, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN), Takeda Pharmaceutical Company Limited (TOKYO:4502) and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the ... |
| | | 03/12/10 | Seattle Genetics to Present at Upcoming Investor Conferences| SEATTLE, Mar 12, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that management will present at two upcoming investor conferences.
WBBA Life Science Innovation Northwest
Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present a company overview on Tuesday, March 16, 2010, at 2:35 p.m. Pacific Time. Dr. Siegall will also participate on a panel, "From IP to IPO: The Journey to Initial Public Offering," on the same date at 4:00 p.m. Pacific Time.... |
| | | 03/11/10 | Seattle Genetics Expands Antibody-Drug Conjugate Patent Portfolio|
- Issued U.S. Patent Extends Patent Protection for Brentuximab Vedotin (SGN-35) to at Least 2025 -
BOTHELL, Wash., Mar 11, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics' ADC programs, most notably brentuximab vedotin (SGN... |
| | | 03/03/10 | Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Genentech| BOTHELL, Wash., Mar 03, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). The milestone was triggered by Genentech's submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for an ADC utilizing Seattle Genetics' technology for the treatmen... |
| | | 02/25/10 | Seattle Genetics to Present at Upcoming Investor Conferences| BOTHELL, Wash., Feb 25, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investors and News" section.
RBC Capital Markets Healthcare Conference
Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present on a panel, "Building a Proprietary and Partnered ... |
| | | 02/09/10 | Seattle Genetics Reports Fourth Quarter and Year 2009 Financial Results and Provides 2010 Financial Outlook| -More than $120 million generated during 2009 from collaboration activities--Conference call today at 5:00 p.m. ET-BOTHELL, Wash., Feb 09, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2009. The company also highlighted recent product development activities and planned milestones and provided its 2010 financial outlook.
"In 2009 we made significant progress with our product pipeline, signed a str... |
| | | 02/03/10 | Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma| BOTHELL, Wash., Feb 03, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refracto... |
| | | 02/02/10 | Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2009 Financial Results on February 9, 2010| BOTHELL, Wash., Feb 02, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it will report its fourth quarter and year 2009 financial results on Tuesday, February 9, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Tuesday, February 9, 2010, 2:00 p.m. Paci... |
| | | 01/05/10 | Seattle Genetics to Present at the J.P. Morgan Healthcare Conference| BOTHELL, Wash., Jan 05, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 28th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2010, at 11:00 a.m. Pacific Time. A live webcast of the presentation will be available from Seattle Genetics' website, www.seattlegenetics.com, under the "Investor and News" section. The conference is being held at the Westin St. Francis Hotel... |
| |
|
